Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
Lake Street analyst Frank Takkinen maintains $NeuroPace(NPCE.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 46.9% and a
NeuroPace (NPCE) Gets a Buy From Lake Street
Press Release: NeuroPace Strengthens Management Team With Two Key Appointments
NeuroPace to Participate in Upcoming Healthcare Conferences in September
NeuroPace Second Quarter 2024 Earnings: Beats Expectations
Earnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57
A Quick Look at Today's Ratings for NeuroPace(NPCE.US), With a Forecast Between $8 to $20
On Aug 15, major Wall Street analysts update their ratings for $NeuroPace(NPCE.US)$, with price targets ranging from $8 to $20.Morgan Stanley analyst Drew Ranieri maintains with a hold rating, and
Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15.
Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
NeuroPace Is Maintained at Overweight by Wells Fargo
NeuroPace Analyst Ratings
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15
Wells Fargo analyst Vik Chopra maintains $NeuroPace(NPCE.US)$ with a buy rating, and adjusts the target price from $20 to $15.According to TipRanks data, the analyst has a success rate of 20.0% and
Earnings Call Summary | NeuroPace(NPCE.US) Q2 2024 Earnings Conference
Express News | Neuropace, Inc. : Wells Fargo Cuts Target Price to $15 From $20
Microelectronic Medical Implants Market Report 2024-2029, With Profiles of Leading Players, Including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro
Express News | Neuropace Inc : JP Morgan Cuts Target Price to $9 From $17
NeuroPace | 10-Q: Q2 2024 Earnings Report
NeuroPace Q2 2024 GAAP EPS $(0.26) Beats $(0.31) Estimate, Sales $19.256M Beat $18.297M Estimate
NeuroPace 2Q Rev $19.3M >NPCE
NeuroPace 2Q Loss/Shr 26c >NPCE